A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

ConditionsAdvanced or Metastatic Adrenocortical Carcinoma Metastatic Castration-resistant Prostate Cancer

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorDaiichi Sankyo

About this trial

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Eligibility criteria

Qualifiers

Sign and date the main ICF, prior to the start of any trial-specific procedures.

Adults ≥18 years of age at the time the ICF is signed (Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old)

Histologically confirmed diagnosis of ACC or adenocarcinoma of the prostate

ECOG PS of 0 or 1 assessed no more than 14 days prior to C1D1. (ECOG PS of 2 due to cancer pain is acceptable)

Disqualifiers

None

Trial design

Treatments tested in this trial

DS9051b

Treatment groups

40 Participants

are divided into 1 treatment group

Sponsors and collaborators

Daiichi Sankyo

Lead sponsor

Source ClinicalTrials.gov